Stevens, J. L. & Baker, T. K. The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discov. Today 14, 162–167. https://doi.org/10.1016/j.drudis.2008.11.009 (2009).

Article  PubMed  Google Scholar 

Watkins, P. B. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89, 788–790. https://doi.org/10.1038/clpt.2011.63 (2011).

Article  CAS  PubMed  Google Scholar 

Wysowski, D. K. & Swartz, L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: The importance of reporting suspected reactions. Arch. Intern. Med. 165, 1363–1369. https://doi.org/10.1001/archinte.165.12.1363 (2005).

Article  PubMed  Google Scholar 

Sgro, C. et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 36, 451–455. https://doi.org/10.1053/jhep.2002.34857 (2002).

Article  PubMed  Google Scholar 

Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B. & Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419-1425.e1413. https://doi.org/10.1053/j.gastro.2013.02.006 (2013).

Article  CAS  PubMed  Google Scholar 

Shin, J. et al. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. Pharmacoepidemiol. Drug Saf. 22, 190–198. https://doi.org/10.1002/pds.3388 (2013).

Article  PubMed  Google Scholar 

Vega, M. et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf. 40, 783–787. https://doi.org/10.1007/s40264-017-0547-9 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen, T. et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 156, 2230-2241.e2211. https://doi.org/10.1053/j.gastro.2019.02.002 (2019).

Article  PubMed  Google Scholar 

Schiødt, F. V. et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl. Surg. 5, 29–34. https://doi.org/10.1002/lt.500050102 (1999).

Article  PubMed  Google Scholar 

Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947–954. https://doi.org/10.7326/0003-4819-137-12-200212170-00007 (2002).

Article  PubMed  Google Scholar 

Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W. & Watkins, P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10, 1018–1023. https://doi.org/10.1002/lt.20204 (2004).

Article  PubMed  Google Scholar 

Bernal, W., Auzinger, G., Dhawan, A. & Wendon, J. Acute liver failure. Lancet 376, 190–201. https://doi.org/10.1016/S0140-6736(10)60274-7 (2010).

Article  PubMed  Google Scholar 

Chalasani, N. P. et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 109, 950–966. https://doi.org/10.1038/ajg.2014.131 (2014).

Article  PubMed  Google Scholar 

Chalasani, N. & Björnsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138, 2246–2259. https://doi.org/10.1053/j.gastro.2010.04.001 (2010).

Article  CAS  PubMed  Google Scholar 

Fontana, R. J. et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147, 96-108.e104. https://doi.org/10.1053/j.gastro.2014.03.045 (2014).

Article  CAS  PubMed  Google Scholar 

Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 148, 1340-1352.e1347. https://doi.org/10.1053/j.gastro.2015.03.006 (2015).

Article  PubMed  Google Scholar 

Andrade, R. J. et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 129, 512–521. https://doi.org/10.1053/j.gastro.2005.05.006 (2005).

Article  PubMed  Google Scholar 

Ball, P., Mandell, L., Niki, Y. & Tillotson, G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 21, 407–421. https://doi.org/10.2165/00002018-199921050-00005 (1999).

Article  CAS  PubMed  Google Scholar 

Shaw, P. J., Hopfensperger, M. J., Ganey, P. E. & Roth, R. A. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol. Sci. 100, 259–266. https://doi.org/10.1093/toxsci/kfm218 (2007).

Article  CAS  PubMed  Google Scholar 

Sarro, D. A. & Sarro, D. G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 8, 371–384. https://doi.org/10.2174/0929867013373435 (2001).

Article  PubMed  Google Scholar 

Van Bambeke, F. & Tulkens, P. M. Safety profile of the respiratory fluoroquinolone moxifloxacin. Drug Saf. 32, 359–378. https://doi.org/10.2165/00002018-200932050-00001 (2009).

Article  PubMed  Google Scholar 

Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67. https://doi.org/10.1006/rtph.2000.1399 (2000).

Article  CAS  PubMed  Google Scholar 

Butler, L. D. et al. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective. Regul. Toxicol. Pharmacol. 87, S1–S15. https://doi.org/10.1016/j.yrtph.2017.05.009 (2017).

Article  PubMed  Google Scholar 

Nguyen, D. G. et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PloS One 11, e0158674. https://doi.org/10.1371/journal.pone.0158674 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, F., Cao, L., Parikh, S. & Zuo, R. Three-dimensional spheroids with primary human liver cells and differential roles of Kupffer cells in drug-induced liver injury. J. Pharm. Sci. 109, 1912–1923. https://doi.org/10.1016/j.xphs.2020.02.021 (2020).

Article  CAS  PubMed  Google Scholar 

Vernetti, L. A. et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp. Biol. Med. (Maywood) 241, 101–114. https://doi.org/10.1177/1535370215592121 (2016).

Article  CAS  PubMed  Google Scholar 

Ewart, L. et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun. Med. 2, 154. https://doi.org/10.1038/s43856-022-00209-1 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Rennert, K. et al. A microfluidically perfused three dimensional human liver model. Biomaterials 71, 119–131. https://doi.org/10.1016/j.biomaterials.2015.08.043 (2015).

Article  CAS  PubMed  Google Scholar 

Kaden, T. et al. Generation & characterization of expandable human liver sinusoidal endothelial cells and their application to assess hepatotoxicity in an advanced in vitro liver model. Toxicology 483, 153374. https://doi.org/10.1016/j.tox.2022.153374 (2023).

Article  CAS  PubMed  Google Scholar 

Spiess, M. The asialoglycoprotein receptor: A model for endocytic transport receptors. Biochemistry 29, 10009–10018. https://doi.org/10.1021/bi00495a001 (1990).

Article  CAS  PubMed  Google Scholar 

Shi, B., Abrams, M. & Sepp-Lorenzino, L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J. Histochem. Cytochem. 61, 901–909. https://doi.org/10.1369/0022155413503662 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cerec, V. et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45, 957–967. https://doi.org/10.1002/hep.21536 (2007).

Article  CAS  PubMed  Google Scholar 

Hayes, J. D., Flanagan, J. U. & Jowsey, I. R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51–88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857 (2004).

Article  CAS  Google Scholar 

Smedsrød, B. Clearance function of scavenger endothelial cells. Comp. Hepatol. 3(Suppl 1), S22–S22. https://doi.org/10.1186/1476-5926-2-S1-S22 (2004).

Article  PubMed  PubMed Central  Google Scholar 

Taylor, P. R. et al. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23, 901–944. https://doi.org/10.1146/annurev.immunol.23.021704.115816 (2004).

Article  CAS  Google Scholar 

Shaw, P. J., Ganey, P. E. & Roth, R. A. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol. Sci. 118, 7–18. https://doi.org/10.1093/toxsci/kfq168 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsiao, C.-J.J., Younis, H. & Boelsterli, U. A. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem. Biol. Interact. 188, 204–213. https://doi.org/10.1016/j.cbi.2010.07.017 (2010).

Article  CAS  PubMed  Google Scholar 

Ito, Y., Bethea, N. W., Abril, E. R. & McCuskey, R. S. Early hepatic microvascular injury in response to acetaminophen toxicity. Microcirculation 10, 391–400. https://doi.org/10.1038/sj.mn.7800204 (2003).

Article  CAS  PubMed  Google Scholar 

Kostadinova, R. et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268, 1–16. https://doi.org/10.1016/j.taap.2013.01.012 (2013).

Article  CAS  PubMed  Google Scholar 

Waring, J. F. et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316, 1080. https://doi.org/10.1124/jpet.105.096347 (2006).

Article  CAS  PubMed  Google Scholar 

Shaw, P. J. et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol. Sci. 107, 270–280. https://doi.org/10.1093/toxsci/kfn205 (2009).

Article  CAS  PubMed  Google Scholar 

Shaw, P. J. et al. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol. Sci. 111, 288–301. https://doi.org/10.1093/toxsci/kfp163 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw, P. J., Ganey, P. E. & Roth, R. A. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J. Pharmacol. Exp. Ther. 328, 62–68. https://doi.org/10.1124/jpet.108.143792 (2009).

Article  CAS  PubMed  Google Scholar 

Giustarini, G. et al. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice. J. Appl. Toxicol. 38, 753–765. https://doi.org/10.1002/jat.3585 (2018).

Article  CAS  PubMed  Google Scholar 

Giustarini, G. et al. Trovafloxacin-induced liver injury: Lack in regulation of inflammation by inhibition of nucleotide release and neutrophil movement. Toxicol Sci 167, 385–396. https://doi.org/10.1093/toxsci/kfy244 (2019).

Article  CAS  PubMed  Google Scholar 

Poon, I. K. H. et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature 507, 329–334. https://doi.org/10.1038/nature13147 (2014).

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Giustarini, G. et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol. Appl. Pharmacol. 391, 114915. https://doi.org/10.1016/j.taap.2020.114915 (2020).

Article  CAS  PubMed  Google Scholar 

Bradham, C. A., Plümpe, J., Manns, M. P., Brenner, D. A. & Trautwein, C. I. TNF-induced liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 275, 387–392. https://doi.org/10.1152/ajpgi.1998.275.3.G387 (1998).

Article  Google Scholar 

Woolbright, B. L. & Jaeschke, H. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. Curr. Pharmacol. Rep. 4, 346–357. https://doi.org/10.1007/s40495-018-0147-0 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonzo, J. A. et al. Differential effects of trovafloxacin on TNF-α and IL-6 profiles in a rat hepatocyte-Kupffer cell coculture system. Appl. Vitro Toxicol. 1, 45–54. https://doi.org/10.1089/aivt.2014.0004 (2015).

Article  CAS  Google Scholar 

Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: From physiopathology to therapy. J. Hepatol. 64, 1403–1415. https://doi.org/10.1016/j.jhep.2016.02.004 (2016).

Article  CAS  PubMed  Google Scholar 

Masubuchi, Y. et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun. 304, 207–212. https://doi.org/10.1016/S0006-291X(03)00572-2 (2003).

Article  CAS  PubMed  Google Scholar 

Kovalovich, K. et al. Increased toxin-induced liver injury and fibrosis in interleukin-6–deficient mice. Hepatology 31, 149–159. https://doi.org/10.1002/hep.510310123 (2000).

Article  CAS  PubMed  Google Scholar 

Feder, L. S., Todaro, J. A. & Laskin, D. L. Characterization of interleukin-1 and interleukin-6 production by hepatic endothelial cells and macrophages. J. Leukoc. Biol. 53, 126–132. https://doi.org/10.1002/jlb.53.2.126 (1993).

Article  CAS  PubMed  Google Scholar 

Vidal-Vanaclocha, F. et al. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. 97, 734–739. https://doi.org/10.1073/pnas.97.2.734 (2000).

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Wu, J. et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 129, 363–374. https://doi.org/10.1111/j.1365-2567.2009.03179.x (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, Y., Zhang, Y., Liu, Y., Xu, J. & Liu, Y. Gut-liver axis: Liver sinusoidal endothelial cells function as the hepatic barrier in colitis-induced liver injury. Front. Cell Dev. Biol. 9, 702890. https://doi.org/10.3389/fcell.2021.702890 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Dong, W. et al. Toxic metals stimulate inflammatory cytokines in hepatocytes through oxidative stress mechanisms. Toxicol. Appl. Pharmacol. 151, 359–366. https://doi.org/10.1006/taap.1998.8481 (1998).

Article  CAS  PubMed  Google Scholar 

Thornton, A. J., Strieter, R. M., Lindley, I., Baggiolini, M. & Kunkel, S. L. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J. Immunol. 144, 2609 (1990).

Article  CAS  PubMed  Google Scholar 

González-Amaro, R. et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J. Exp. Med. 179, 841–848. https://doi.org/10.1084/jem.179.3.841 (1994).

Article  PubMed  Google Scholar 

Saad, B., Frei, K., Scholl, F. A., Fontana, A. & Maier, P. Hepatocyte-derived Interleukin-6 and tumor-necrosis factor α mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. Eur. J. Biochem. 229, 349–355. https://doi.org/10.1111/j.1432-1033.1995.0349k.x (1995).

Article  CAS  PubMed  Google Scholar 

Tanaka, Y., Yamato, M., Okano, T., Kitamori, T. & Sato, K. Evaluation of effects of shear stress on hepatocytes by a microchip-based system. Meas. Sci. Technol. 17, 3167. https://doi.org/10.1088/0957-0233/17/12/S08 (2006).

Article  CAS  Google Scholar 

DeLeve, L. D., Wang, X., Hu, L., McCuskey, M. K. & McCuskey, R. S. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G757–G763. https://doi.org/10.1152/ajpgi.00017.2004 (2004).

Article  CAS  PubMed  Google Scholar 

Liguori, M. J. et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41, 177–186. https://doi.org/10.1002/hep.20514 (2005).

Article  CAS  PubMed  Google Scholar 

Guillouzo, A. et al. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66–73. https://doi.org/10.1016/j.cbi.2006.12.003 (2007).

Article  CAS  PubMed  Google Scholar 

Kanebratt, K. P. & Andersson, T. B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36, 1444. https://doi.org/10.1124/dmd.107.020016 (2008).

Article  CAS  PubMed  Google Scholar 

Lübberstedt, M. et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 63, 59–68. https://doi.org/10.1016/j.vascn.2010.04.013 (2011).

Article  CAS  PubMed  Google Scholar 

Nelson, L. J. et al. Human hepatic HepaRG cells maintain an organotypic phenotype with high intrinsic CYP450 activity/metabolism and significantly outperform standard HepG2/C3A cells for pharmaceutical and therapeutic applications. Basic Clin. Pharmacol. Toxicol. 120, 30–37. https://doi.org/10.1111/bcpt.12631 (2017).

Article  CAS  PubMed  Google Scholar 

Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V. & Vinken, M. Primary hepatocyte cultures for pharmaco-toxicological studies: At the busy crossroad of various anti-dedifferentiation strategies. Arch. Toxicol. 87, 577–610. https://doi.org/10.1007/s00204-012-0983-3 (2013).

Article  CAS  PubMed  Google Scholar 

Elvevold, K., Smedsrød, B. & Martinez, I. The liver sinusoidal endothelial cell: A cell type of controversial and confusing identity. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G391–G400. https://doi.org/10.1152/ajpgi.00167.2007 (2008).

Article  CAS  PubMed  Google Scholar 

Heuff, G., Van Loosdrecht, A. A. D., Betjes, M. G. H., Beelen, R. H. J. & Meijer, S. Isolation and purification of large quantities of fresh human Kupffer cells, which are cytotoxic against colon carcinoma. Hepatology 21, 740–745. https://doi.org/10.1002/hep.1840210322 (1995).

Article  CAS  PubMed  Google Scholar 

Raasch, M., Fritsche, E., Kurtz, A., Bauer, M. & Mosig, A. S. Microphysiological systems meet hiPSC technology—New tools for disease modeling of liver infections in basic research and drug development. Adv. Drug Deliv. Rev. 140, 51–67. https://doi.org/10.1016/j.addr.2018.06.008 (2019).

Article  CAS  PubMed  Google Scholar 

Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. 99, 15655–15660. https://doi.org/10.1073/pnas.232137699 (2002).

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Kmiec, Z. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Boil. 161, III–XIII, 1, Doi: https://doi.org/10.1007/978-3-642-56553-3_7 (2001).

Lalor, P. F. & Adams, D. H. Adhesion of lymphocytes to hepatic endothelium. Mol. Pathol. 52, 214–219. https://doi.org/10.1136/mp.52.4.214 (1999).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rashidi, H., Alhaque, S., Szkolnicka, D., Flint, O. & Hay, D. C. Fluid shear stress modulation of hepatocyte-like cell function. Arch. Toxicol. 90, 1757–1761. https://doi.org/10.1007/s00204-016-1689-8 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu, J. J. et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97–105. https://doi.org/10.1093/toxsci/kfn109 (2008).

Article  CAS  PubMed  Google Scholar 

Fish, D. N. & Chow, A. T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32, 101–119. https://doi.org/10.2165/00003088-199732020-00002 (1997).

Article  CAS  PubMed  Google Scholar 

Vincent, J., Teng, R., Dalvie, D. K. & Friedman, H. L. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am. J. Surg. 176, 8S-13S. https://doi.org/10.1016/S0002-9610(98)00213-X (1998).

Article  CAS  PubMed  Google Scholar 

Teng, R. et al. Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36, 385–394. https://doi.org/10.1093/jac/36.2.385 (1995).

Article  CAS  PubMed  Google Scholar 

Lubasch, A., Keller, I., Borner, K., Koeppe, P. & Lode, H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44, 2600–2603. https://doi.org/10.1128/AAC.44.10.2600-2603.2000 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar